Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2011 - 2026)

Regeneron Pharmaceuticals' Long-Term Deferred Tax history runs 16 years deep, the most recent figure standing at $4.2 billion for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 21.73% year-over-year to $4.2 billion in Q1 2026; TTM through Mar 2026 was $4.2 billion, a 21.73% increase from a year earlier, with the FY2025 full-year figure at $4.1 billion, up 23.03% from the prior year.
• Long-Term Deferred Tax advanced to $4.2 billion in Q1 2026 per REGN's latest filing, from $4.1 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $4.2 billion in Q1 2026 and bottomed at $1.1 billion in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $2.8 billion (2024), against an average of $2.7 billion.
• Across the five-year window, Long-Term Deferred Tax soared 100.79% in 2022 and grew 21.73% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $1.7 billion in 2022, then surged by 49.41% to $2.6 billion in 2023, then gained by 28.68% to $3.3 billion in 2024, then rose by 23.03% to $4.1 billion in 2025, then gained by 2.79% to $4.2 billion in 2026.
• Per Business Quant, the three latest REGN Long-Term Deferred Tax figures stand at $4.2 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.8 billion (Q3 2025).